Fiche publication
Date publication
juillet 2024
Journal
Multiple sclerosis and related disorders
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
,
Dr NOBLET Vincent
Tous les auteurs :
Pfaff L, Mondino M, Loeb Q, Noblet V, Berthe C, Kremer L, Bigaut K, Collongues N, De Seze J
Lien Pubmed
Résumé
As cognitive impairment in multiple sclerosis (MS) is a frequent and disabling symptom, it is particularly important to identify treatments that have proven efficacy in this aspect of the disease. Several disease-modifying therapies for MS have been evaluated and shown to have a potential effect on cognition and its neurobiological correlates, but to date there is very little data on Teriflunomide (TRF). The aim of this study is to explore the influence of TRF on comprehensive cognitive function and its MRI correlations (global and focal brain volume) in relapsing-remitting multiple sclerosis (RRMS) after two years of therapy.
Mots clés
Cognition, MRI, Teriflunomide, Treatment
Référence
Mult Scler Relat Disord. 2024 07 31;90:105793
